These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 21931118)

  • 1. Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412.
    Römer PS; Berr S; Avota E; Na SY; Battaglia M; ten Berge I; Einsele H; Hünig T
    Blood; 2011 Dec; 118(26):6772-82. PubMed ID: 21931118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Failure to upregulate cell surface PD-1 is associated with dysregulated stimulation of T cells by TGN1412-like CD28 superagonist.
    Thaventhiran T; Alhumeed N; Yeang HX; Sethu S; Downey JS; Alghanem AF; Olayanju A; Smith EL; Cross MJ; Webb SD; Williams DP; Bristow A; Ball C; Stebbings R; Sathish JG
    MAbs; 2014; 6(5):1290-9. PubMed ID: 25517314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells.
    Eastwood D; Findlay L; Poole S; Bird C; Wadhwa M; Moore M; Burns C; Thorpe R; Stebbings R
    Br J Pharmacol; 2010 Oct; 161(3):512-26. PubMed ID: 20880392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412.
    Hussain K; Hargreaves CE; Roghanian A; Oldham RJ; Chan HT; Mockridge CI; Chowdhury F; Frendéus B; Harper KS; Strefford JC; Cragg MS; Glennie MJ; Williams AP; French RR
    Blood; 2015 Jan; 125(1):102-10. PubMed ID: 25395427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies.
    Waibler Z; Sender LY; Merten C; Hartig R; Kliche S; Gunzer M; Reichardt P; Kalinke U; Schraven B
    PLoS One; 2008 Mar; 3(3):e1708. PubMed ID: 18320029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08.
    Tabares P; Berr S; Römer PS; Chuvpilo S; Matskevich AA; Tyrsin D; Fedotov Y; Einsele H; Tony HP; Hünig T
    Eur J Immunol; 2014 Apr; 44(4):1225-36. PubMed ID: 24374661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A simple whole blood bioassay detects cytokine responses to anti-CD28SA and anti-CD52 antibodies.
    Bailey L; Moreno L; Manigold T; Krasniqi S; Kropshofer H; Hinton H; Singer T; Suter L; Hansel TT; Mitchell JA
    J Pharmacol Toxicol Methods; 2013; 68(2):231-239. PubMed ID: 23280407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphatidylserine-Targeting Monoclonal Antibodies Exhibit Distinct Biochemical and Cellular Effects on Anti-CD3/CD28-Stimulated T Cell IFN-γ and TNF-α Production.
    Calianese D; Kreiss T; Kasikara C; Davra V; Lahey KC; Gadiyar V; Geng K; Singh S; Honnen W; Jaijyan DK; Reichman C; Siekierka J; Gennaro ML; Kotenko SV; Ucker DS; Brekken RA; Pinter A; Birge RB; Choudhary A
    J Immunol; 2021 Jul; 207(2):436-448. PubMed ID: 34215655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a TGN1412 analogue using in vitro assays and two immune humanized mouse models.
    Yan H; Bhagwat B; Sanden D; Willingham A; Tan A; Knapton AD; Weaver JL; Howard KE
    Toxicol Appl Pharmacol; 2019 Jun; 372():57-69. PubMed ID: 30914376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Interleukin-12 restores and promotes the T-cell immune function inhibited by 5-fluorouracil].
    Chi PD; Li L; Fan YY; Wu CY
    Ai Zheng; 2007 Aug; 26(8):801-8. PubMed ID: 17697537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advantages of Papio anubis for preclinical testing of immunotoxicity of candidate therapeutic antagonist antibodies targeting CD28.
    Poirier N; Mary C; Le Bas-Bernardet S; Daguin V; Belarif L; Chevalier M; Hervouet J; Minault D; Ville S; Charpy V; Blancho G; Vanhove B
    MAbs; 2014; 6(3):697-707. PubMed ID: 24598534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Korean mistletoe lectin (Viscum album coloratum) on proliferation and cytokine expression in human peripheral blood mononuclear cells and T-lymphocytes.
    Lyu SY; Park WB
    Arch Pharm Res; 2007 Oct; 30(10):1252-64. PubMed ID: 18038904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. After TGN1412: recent developments in cytokine release assays.
    Stebbings R; Eastwood D; Poole S; Thorpe R
    J Immunotoxicol; 2013; 10(1):75-82. PubMed ID: 22967038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release.
    Eastwood D; Bird C; Dilger P; Hockley J; Findlay L; Poole S; Thorpe SJ; Wadhwa M; Thorpe R; Stebbings R
    Br J Clin Pharmacol; 2013 Aug; 76(2):299-315. PubMed ID: 23701319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Were monocytes responsible for initiating the cytokine storm in the TGN1412 clinical trial tragedy?
    Sandilands GP; Wilson M; Huser C; Jolly L; Sands WA; McSharry C
    Clin Exp Immunol; 2010 Dec; 162(3):516-27. PubMed ID: 20964641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of a novel fully human non-superagonistic anti-CD28 antibody with efficient and safe T-cell co-stimulation properties.
    Elsayed A; Pellegrino C; Plüss L; Peissert F; Benz R; Ulrich F; Thorhallsdottir G; Plaza SD; Villa A; Mock J; Puca E; De Luca R; Manz MG; Halin C; Neri D
    MAbs; 2023; 15(1):2220839. PubMed ID: 37288872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD3/anti-CD28 monoclonal antibody-coated suture enhances the immune response of patients with head and neck squamous cell carcinoma.
    Shibuya TY; Wei WZ; Zormeier M; Ensley J; Sakr W; Mathog RH; Meleca RJ; Yoo G; June CH; Levine B; Lum LG
    Arch Otolaryngol Head Neck Surg; 1999 Nov; 125(11):1229-34. PubMed ID: 10555694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm.
    Vessillier S; Eastwood D; Fox B; Sathish J; Sethu S; Dougall T; Thorpe SJ; Thorpe R; Stebbings R
    J Immunol Methods; 2015 Sep; 424():43-52. PubMed ID: 25960173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell contact-dependent priming and Fc interaction with CD32+ immune cells contribute to the TGN1412-triggered cytokine response.
    Bartholomaeus P; Semmler LY; Bukur T; Boisguerin V; Römer PS; Tabares P; Chuvpilo S; Tyrsin DY; Matskevich A; Hengel H; Castle J; Hünig T; Kalinke U
    J Immunol; 2014 Mar; 192(5):2091-8. PubMed ID: 24470499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412.
    Findlay L; Eastwood D; Stebbings R; Sharp G; Mistry Y; Ball C; Hood J; Thorpe R; Poole S
    J Immunol Methods; 2010 Jan; 352(1-2):1-12. PubMed ID: 19895813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.